Results 121 to 130 of about 36,523 (216)

Correction to: Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. [PDF]

Oncologist
europepmc   +2 more sources

Karl Ludwig Giesecke : his albums and his likely involvement in the writing of the libretto of Mozart's opera The Magic Flute [PDF]

, 2009
Whittaker, Alfred
core  

Matching-adjusted indirect comparison of selpercatinib and pralsetinib in <i>RET</i> fusion-positive non-small cell lung cancer. [PDF]

Future Oncol
Hochmair M, Kiiskinen U, D'yachkova Y, Puri T, Wang X, Wolowacz S, Vickers A, Nadal E.   +7 more
europepmc   +1 more source

Preoperative selpercatinib induces major pathological response in a patient with stage IIIA, RET fusion-positive non-small cell lung cancer: A case report. [PDF]

Medicine (Baltimore)
Breitenecker K, Fabikan H, Weinlinger C, Krenbek D, Klikovits T, Watzka S, Valipour A, Hochmair MJ.   +7 more
europepmc   +1 more source

Communicating clinical trial information about cancer drug products to patients and healthcare professionals: review of patient-reported outcome messaging. [PDF]

BMJ Oncol
Shahraz S, Wong OY, Chotai R, Knight S, Globe D, Patel MJ, Kaushik A, Aiyegbusi OL, Calvert M.   +8 more
europepmc   +1 more source

Tannhäuser’s dilemma: a counterfactual analysis [PDF]

, 2008
Harmgart, H., Huck, S., Muller, W.
core  

Selpercatinib in Chinese patients with <i>RET</i>-fusion-positive non-small-cell lung cancer: updated efficacy and safety analysis from the LIBRETTO-321 phase II trial. [PDF]

Ther Adv Med Oncol
Lu S, Cheng Y, Huang D, Sun Y, Wu L, Zhou C, Zhou J, Guo Y, Shao J, Zhang W.   +9 more
europepmc   +1 more source

Molecular-Level Insights into the Reaction Mechanisms of Reductive Etherification for the Production of Synthetic Biofuels. [PDF]

ACS Omega
Doan HA, Li C, Miller JH, LiBretto NJ, Rein AL, Zhou M, Hafenstine GR, Vardon DR, Habas SE, Assary RS.   +9 more
europepmc   +1 more source

Mechanism of and research progress on alterations in the RET gene in thyroid cancer (Review). [PDF]

Mol Med Rep
Wei M, Wang R, Qian J, Fang Q, Tao J.
europepmc   +1 more source

Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in <i>RET</i> Fusion-Positive NSCLC. [PDF]

JTO Clin Res Rep
Zhou C, Novello S, Garrido P, Dooms C, Alatorre-Alexander J, Reinmuth N, Worthy G, Cocks K, Williams J, Han H, Uh MK, Payakachat N, Gilligan AM, Goto K.   +13 more
europepmc   +1 more source